23 June 2010

SAREUM HOLDINGS PLC
(“Sareum” or the “Company”)

Sareum to Present at EPIC 2010

Sareum (AIM: SAR), the specialist cancer drug discovery business, is pleased to announce that Dr Tim Mitchell, CEO, will present Sareum’s cancer research programmes and SKIL technology platform at the European Partnering and Investment Conference (“EPIC”) later today.

EPIC takes place annually in London and showcases the best of European biotechnology companies to an audience of 250-300 delegates including the pharmaceutical, biotechnology and investor sectors.

Sareum’s CEO, Dr Tim Mitchell, commented: “This is a further opportunity for us to present our drug research programmes and the technology behind them to potential customers and investors at an international partnering conference.”

Notes for editors:

About Sareum Holdings plc

Sareum is a drug discovery company, headquartered in Cambridge UK, that is focused on producing targeted small molecule therapeutics to address unmet medical needs, primarily in cancer. Sareum aims to successfully deliver drug candidates for licensing to pharmaceutical and biotechnology companies at the pre-clinical or early clinical trials stage.

Sareum’s Chk1 kinase cancer research programme is a joint research collaboration with The Institute of Cancer Research and Cancer Research Technology Limited. Novel chemical compounds developed by the collaboration have been shown to increase the effectiveness of current cancer therapeutics in in-vivo cancer models.

SKIL (Sareum Kinase Inhibitor Library) is Sareum’s drug discovery technology platform that has so far produced the Company’s Aurora, VEGFR-3 and FLT3 kinase cancer and auto-immune disease research programmes. SKIL can also generate drug research programmes against other kinase targets.

Sareum Holdings plc joined the AIM market of the London Stock Exchange in October 2004, trading under the symbol SAR.  For further information, please visit www.sareum.co.uk